Skip to main content
OpenTrials
Completed

NCT Number: NCT01604798

Serum Proteomic Profiling for the Early Diagnosis of Colorectal Cancer

No ideal serum biomarker currently exists for the early diagnosis of colorectal cancer (CRC). Therefore, it is urgent that accurate and reliable serum biomarkers be identified.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Colorectal Neoplasms Colonic Diseases Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site Rectal Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

About this study

Magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) was used to screen serum samples from CRC patients and healthy controls.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Patients with colorectal cancer

Inclusion criteria

  • histologically confirmed colorectal cancer
  • aged 18 years or older
  • have provided written informed consent

Exclusion criteria

  • refusal to participate

Healthy controls

Inclusion criteria

  • no cancer history
  • aged 18 years or older
  • have provided written informed consent

Exclusion criteria

  • refusal to participate
  • have first-degree relative with a known history of colorectal cancer

Treatment and study plan

Serum proteomics

Other

magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry

Other names: MB coupled with MALDI-TOF MS

Primary outcomes

  1. Serum peptide mass fingerprinting (PMF)

    Time frame: 2010.03-2012.05 (2 years)

    Compare PMF of the colorectal caner group and control group, and then build the model to distinguish patients with colorectal cancer and controls

Secondary outcomes

  1. Expressed peptide peaks

    Time frame: 2010.03-2012.05 (2 years)

    Find differentially expressed peptide peaks from the model and identify some ideal serum biomarkers for the early diagnosis of colorectal cancer

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
May 24, 2012
Registry last updated
May 24, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.